160 related articles for article (PubMed ID: 20533032)
1. Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy.
Gilardi L; De Cicco C; Colleoni M; Cardillo A; Montagna E; Dellapasqua S; Galimberti V; Bagnardi V; Paganelli G
Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1834-41. PubMed ID: 20533032
[TBL] [Abstract][Full Text] [Related]
2. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.
Veronesi U; De Cicco C; Galimberti VE; Fernandez JR; Rotmensz N; Viale G; Spano G; Luini A; Intra M; Veronesi P; Berrettini A; Paganelli G
Ann Oncol; 2007 Mar; 18(3):473-8. PubMed ID: 17164229
[TBL] [Abstract][Full Text] [Related]
3. Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging.
Taira N; Ohsumi S; Takabatake D; Hara F; Takashima S; Aogi K; Takashima S; Inoue T; Sugata S; Nishimura R
Jpn J Clin Oncol; 2009 Jan; 39(1):16-21. PubMed ID: 18997183
[TBL] [Abstract][Full Text] [Related]
4. Selective Sentinel Node Plus Additional Non-Sentinel Node Biopsy Based on an FDG-PET/CT Scan in Early Breast Cancer Patients: Single Institutional Experience.
Kim J; Lee J; Chang E; Kim S; Suh K; Sul J; Song I; Kim Y; Lee C
World J Surg; 2009 May; 33(5):943-9. PubMed ID: 19259728
[TBL] [Abstract][Full Text] [Related]
5. The predictive value of sentinel node biopsy in early breast cancer after neo-adjuvant chemotherapy: A prospective study.
Najim O; Dockx Y; Huyghe I; van den Wyngaert T; Papadimitriou K; Tjalma WAA; Huizing MT
Eur J Obstet Gynecol Reprod Biol; 2018 Oct; 229():108-111. PubMed ID: 30145524
[TBL] [Abstract][Full Text] [Related]
6. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.
Ueda S; Tsuda H; Asakawa H; Omata J; Fukatsu K; Kondo N; Kondo T; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
BMC Cancer; 2008 Jun; 8():165. PubMed ID: 18541009
[TBL] [Abstract][Full Text] [Related]
7. Subtype-Guided
Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
[TBL] [Abstract][Full Text] [Related]
8. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
Greco M; Crippa F; Agresti R; Seregni E; Gerali A; Giovanazzi R; Micheli A; Asero S; Ferraris C; Gennaro M; Bombardieri E; Cascinelli N
J Natl Cancer Inst; 2001 Apr; 93(8):630-5. PubMed ID: 11309439
[TBL] [Abstract][Full Text] [Related]
9. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer.
van der Hoeven JJ; Hoekstra OS; Comans EF; Pijpers R; Boom RP; van Geldere D; Meijer S; Lammertsma AA; Teule GJ
Ann Surg; 2002 Nov; 236(5):619-24. PubMed ID: 12409668
[TBL] [Abstract][Full Text] [Related]
10. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
[TBL] [Abstract][Full Text] [Related]
11. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
[TBL] [Abstract][Full Text] [Related]
12. Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study.
Pritchard KI; Julian JA; Holloway CM; McCready D; Gulenchyn KY; George R; Hodgson N; Lovrics P; Perera F; Elavathil L; O'Malley FP; Down N; Bodurtha A; Shelley W; Levine MN
J Clin Oncol; 2012 Apr; 30(12):1274-9. PubMed ID: 22393089
[TBL] [Abstract][Full Text] [Related]
13. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients.
Dalus K; Reitsamer R; Holzmannhofer J; Rendl G; Pirich C; Kronberger C; Rettenbacher L
Nuklearmedizin; 2011; 50(1):33-8. PubMed ID: 21336417
[TBL] [Abstract][Full Text] [Related]
14. Prediction of Extracapsular Invasion at Metastatic Sentinel Nodes and Non-sentinel Lymph Nodal Metastases by FDG-PET in Cases with Breast Cancer.
Fujii T; Yajima R; Tatsuki H; Kuwano H
Anticancer Res; 2016 Apr; 36(4):1785-9. PubMed ID: 27069160
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET for axillary lymph node staging in primary breast cancer.
Crippa F; Gerali A; Alessi A; Agresti R; Bombardieri E
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S97-102. PubMed ID: 15133635
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients.
Straver ME; Aukema TS; Olmos RA; Rutgers EJ; Gilhuijs KG; Schot ME; Vogel WV; Peeters MJ
Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1069-76. PubMed ID: 20130860
[TBL] [Abstract][Full Text] [Related]
17. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer.
Gil-Rendo A; Zornoza G; García-Velloso MJ; Regueira FM; Beorlegui C; Cervera M
Br J Surg; 2006 Jun; 93(6):707-12. PubMed ID: 16622900
[TBL] [Abstract][Full Text] [Related]
18. DaPeCa-3: promising results of sentinel node biopsy combined with (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in clinically lymph node-negative patients with penile cancer - a national study from Denmark.
Jakobsen JK; Alslev L; Ipsen P; Costa JC; Krarup KP; Sommer P; Nerstrøm H; Toft BG; Høyer S; Bouchelouche K; Jensen JB
BJU Int; 2016 Jul; 118(1):102-11. PubMed ID: 26216234
[TBL] [Abstract][Full Text] [Related]
19. Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: results and clinical implications after eight-years follow-up.
Agresti R; Crippa F; Sandri M; Martelli G; Tagliabue E; Alessi A; Pellitteri C; Maccauro M; Maugeri I; Barbara P; Rampa M; Moscaroli A; Ferraris C; Carcangiu ML; Bianchi G; Greco M; Bombardieri E
Breast; 2014 Aug; 23(4):334-40. PubMed ID: 24485802
[TBL] [Abstract][Full Text] [Related]
20. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
